A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.

Br J Cancer · 2012 · PMC3388559 · PMID 22555398

Europe PMC DOI

hedged sentence

0.1040

closest p · 2.1× alpha

0.1040

boldest claim

The sentences

did not reach statistical significanceP =0.104not close (p > 0.1)

The improvement in OS did not reach statistical significance, with a hazard ratio of 0.72 (95% CI: 0.48–1.07; P =0.104).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.